IN VIVO TISSUE ENGINEERING: CONCEPT OUTLINE AND ITS REALIZATION WITH BIODEGRADABLE POLYMERS

ASAIO Journal ◽  
1999 ◽  
Vol 45 (2) ◽  
pp. 207
Author(s):  
Ivanka J. Zdrahala ◽  
Richard J. Zdrahala
2005 ◽  
Vol 58 (8) ◽  
pp. 1104-1114 ◽  
Author(s):  
S.O.P. Hofer ◽  
G.M. Mitchell ◽  
A.J. Penington ◽  
W.A. Morrison ◽  
R. RomeoMeeuw ◽  
...  

2018 ◽  
Vol 59 (3-4) ◽  
pp. 286-299 ◽  
Author(s):  
Annika Weigand ◽  
Raymund E. Horch ◽  
Anja M. Boos ◽  
Justus P. Beier ◽  
Andreas Arkudas

Background: Most of the current treatment options for large-scale tissue defects represent a serious burden for the patients, are often not satisfying, and can be associated with significant side effects. Although major achievements have already been made in the field of tissue engineering, the clinical translation in case of extensive tissue defects is only in its early stages. The main challenge and reason for the failure of most tissue engineering approaches is the missing vascularization within large-scale transplants. Summary: The arteriovenous (AV) loop model is an in vivo tissue engineering strategy for generating axially vascularized tissues using the own body as a bioreactor. A superficial artery and vein are anastomosed to create an AV loop. This AV loop is placed into an implantation chamber for prevascularization of the chamber inside, e.g., a scaffold, cells, and growth factors. Subsequently, the generated tissue can be transplanted with its vascular axis into the defect site and anastomosed to the local vasculature. Since the blood supply of the growing tissue is based on the AV loop, it will be immediately perfused with blood in the recipient site leading to optimal healing conditions even in the case of poorly vascularized defects. Using this tissue engineering approach, a multitude of different axially vascularized tissues could be generated, such as bone, skeletal or heart muscle, or lymphatic tissues. Upscaling from the small animal AV loop model into a preclinical large animal model could pave the way for the first successful attempt in clinical application. Key Messages: The AV loop model is a powerful tool for the generation of different axially vascularized replacement tissues. Due to minimal donor site morbidity and the possibility to generate patient-specific tissues variable in type and size, this in vivo tissue engineering approach can be considered as a promising alternative therapy to current treatment options of large-scale defects.


Pathobiology ◽  
2013 ◽  
Vol 80 (4) ◽  
pp. 176-181 ◽  
Author(s):  
Meltem Avci-Adali ◽  
Heidi Stoll ◽  
Nadja Wilhelm ◽  
Nadja Perle ◽  
Christian Schlensak ◽  
...  

Author(s):  
Jin Feng Yao ◽  
Y.Z. Zhang ◽  
C.Y. Bao ◽  
L.Y. Sun ◽  
X.M. Hao ◽  
...  

2013 ◽  
Vol 19 (11-12) ◽  
pp. 1327-1335 ◽  
Author(s):  
Ken Matsuda ◽  
Katrina J. Falkenberg ◽  
Alan A. Woods ◽  
Yu Suk Choi ◽  
Wayne A. Morrison ◽  
...  

2018 ◽  
Vol 6 (3) ◽  
pp. 550-561 ◽  
Author(s):  
Koji Nagahama ◽  
Naho Oyama ◽  
Kimika Ono ◽  
Atsushi Hotta ◽  
Keiko Kawauchi ◽  
...  

Nanocomposite injectable gels, which self-replenish regenerative extracellular microenvironments within the gels in the body by utilizing host-derived bioactive molecules as building blocks, are reported.


2011 ◽  
Vol 1299 ◽  
Author(s):  
Jane Wang ◽  
Tatiana Kniazeva ◽  
Carly F. Campbell ◽  
Robert Langer ◽  
Jeffrey S. Ustin ◽  
...  

ABSTRACTBiodegradable polymers with high mechanical strength, flexibility and optical transparency, optimal degradation properties and biocompatibility are critical to the success of tissue engineered devices and drug delivery systems. In this work, microfluidic devices have been fabricated from elastomeric scaffolds with tunable degradation properties for applications in tissue engineering and regenerative medicine. Most biodegradable polymers suffer from short half life resulting from rapid and poorly controlled degradation upon implantation, exceedingly high stiffness, and limited compatibility with chemical functionalization. Here we report the first microfluidic devices constructed from a recently developed class of biodegradable elastomeric poly(ester amide)s, poly(1,3-diamino-2-hydroxypropane-co-polyol sebacate)s (APS), showing a much longer and highly tunable in vivo degradation half-life comparing to many other commonly used biodegradable polymers. The device is molded in a similar approach to that reported previously for conventional biodegradable polymers, and the bonded microfluidic channels are shown to be capable of supporting physiologic levels of flow and pressure. The device has been tested for degradation rate and gas permeation properties in order to predict performance in the implantation environment. This device is high resolution and fully biodegradable; the fabrication process is fast, inexpensive, reproducible, and scalable, making it the approach ideal for both rapid prototyping and manufacturing of tissue engineering scaffolds and vasculature and tissue and organ replacements.


2012 ◽  
Vol 94 (10S) ◽  
pp. 336
Author(s):  
S. Rohn ◽  
M. T. Mogl ◽  
H. Riedel ◽  
J. Schroeder ◽  
N. Billecke ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document